Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.50 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.50 |
| ▸ | FAP | Q12884 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7348800 | 1.00 | DPP4 (0.50) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL7324906 | 0.98 | DPP4 (0.48) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL7321497 | 0.98 | DPP4 (0.48) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL7354071 | 0.96 | DPP4 (0.47) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL7354079 | 0.96 | DPP4 (0.47) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL29466169 | 0.88 | DPP4 (0.50) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL13086357 | 0.86 | CA12 (0.48) | DPP4CA12CA14BIRC2TSHR | |
| SCHEMBL19425794 | 0.85 | DPP4 (0.47) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL30698081 | 0.84 | CA12 (0.47) | DPP4CA12CA14BIRC2TSHR | |
| SCHEMBL7613644 | 0.84 | BIRC2 (0.45) | CA12CA14BIRC2TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0204775-A4 | AMINO ACID AND PEPTIDE INHIBITORS OF HUMAN LEUCOCYTIC ELASTASE. | UNIV TROBE (AU) | 1989-10-04 | — | — | EP | claimed |
| EP-0204775-A1 | AMINO ACID AND PEPTIDE INHIBITORS OF HUMAN LEUCOCYTIC ELASTASE | AUSTRALIAN COMMERCIAL RESEARCH & DEVELOPMENT LIMITED (AU) | 1986-12-17 | — | — | EP | claimed |
| WO-1986003746-A1 | AMINO ACID AND PEPTIDE INHIBITORS OF HUMAN LEUCOCYTIC ELASTASE | LA TROBE UNIVERSITY (AU) | 1986-07-03 | — | — | WO | claimed |
| EP-3439658-B1 | SOLUBLE C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2021-11-24 | — | — | EP | disclosed |
| US-10329314-B2 | Soluble C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20170283446-A1 | SOLUBLE C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9227995-B2 | Peptides | Jacobsen, Øyvind (NO) | 2016-01-05 | — | — | US | disclosed |
| US-9227995-B2 | Peptides | Jacobsen, Øyvind (NO) | 2016-01-05 | — | — | US | disclosed |
| US-8389764-B2 | Urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2013-03-05 | — | — | US | disclosed |
| US-20110263479-A1 | Peptides | UNIVERSITETET I OSLO (NO) | 2011-10-27 | — | — | US | disclosed |
| US-20110263479-A1 | Peptides | UNIVERSITETET I OSLO (NO) | 2011-10-27 | — | — | US | disclosed |
| EP-0594586-A1 | HIV PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-05-04 | — | — | EP | disclosed |
| WO-1991010442-A1 | HIV PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1991-07-25 | — | — | WO | disclosed |
| WO-1990005141-A1 | AMINO ACID AND PEPTIDE INHIBITORS OF HUMAN LEUKOCYTIC ELASTASE AND COLLAGENASE | AUSTRALIAN COMMERCIAL RESEARCH & DEVELOPMENT LIMITED (AU) | 1990-05-17 | — | — | WO | disclosed |
| CN-1039596-A | Preparation method in conjunction with the peptide of retroviral Protease | SMITHKLINE BECKMAN CORP (US) | 1990-02-14 | — | — | CN | disclosed |
| WO-1990000399-A1 | RETROVIRAL PROTEASE BINDING PEPTIDES | SMITHKLINE BECKMAN CORPORATION (US) | 1990-01-25 | — | — | WO | disclosed |
| EP-0352000-A2 | Retroviral protease binding peptides | SMITHKLINE BEECHAM CORPORATION (US) | 1990-01-24 | — | — | EP | disclosed |
| EP-0204775-A4 | AMINO ACID AND PEPTIDE INHIBITORS OF HUMAN LEUCOCYTIC ELASTASE. | UNIV TROBE (AU) | 1989-10-04 | — | — | EP | disclosed |
| EP-0204775-A1 | AMINO ACID AND PEPTIDE INHIBITORS OF HUMAN LEUCOCYTIC ELASTASE | AUSTRALIAN COMMERCIAL RESEARCH & DEVELOPMENT LIMITED (AU) | 1986-12-17 | — | — | EP | disclosed |
| WO-1986003746-A1 | AMINO ACID AND PEPTIDE INHIBITORS OF HUMAN LEUCOCYTIC ELASTASE | LA TROBE UNIVERSITY (AU) | 1986-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283446-A1 | SOLUBLE C5aR ANTAGONISTS | C5AR1, C3AR1, C5AR2 | DPP4 1748/4885DPP8 1664/4885DPP9 1343/4885 |
| US-20110263479-A1 | Peptides | VIP, NGLY1, NPPA | DPP4 118/4885DPP8 125/4885DPP9 136/4885 |
| US-10329314-B2 | Soluble C5aR antagonists | C5AR1, C3AR1, C5AR2 | DPP4 1748/4885DPP8 1664/4885DPP9 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.